Canine Parvovirus Monoclonal Antibody
CPMA (now TrutectTM) is the first and only monoclonal antibody (mAb) treatment that targets canine parvovirus (CPV) and has been shown to be effective for passive immunity (i.e. Parvovirus Prophylaxis).1
Why choose Canine Parvovirus Monoclonal Antibody?
We anticipate Canine Parvovirus Monoclonal Antibody will help greatly decrease the burden of supportive care for CPV. You may be able to save days of labor and stress associated with managing the symptoms of this potentially deadly disease.
mAb that targets parvovirus directly
Single-dose efficacy
High safety profile
May help decrease burden of supportive care and may help reduce emotional stress
The Results Are In!
Important Information
Canine Parvovirus Monoclonal Antibody is indicated for the treatment and prevention of canine parvovirus infection.
Monoclonal Antibody
Intravenous administration for treatment of active CPV infection
Subcutaneous injection for use as prophylactic
Delivered in unique packaging designed to keep it at ≤ -15°C or ≤ 5°F and should be stored frozen.
Dosing Information
How Canine Parvovirus Monoclonal Antibody Works
Two components. One powerful product.
Canine Parvovirus Monoclonal Antibody is composed of a dog constant region and a rat variable region.
These two elements work together to neutralize canine parvovirus in vivo by selectively binding and blocking the virus from entering and destroying enterocytes.
Pet Owner Resources
CPMA Pet Owner Education Pamphlet
Care Credit Financial Assistance for Pet Owners
Clinic Resources
Educational Videos and Podcasts
Order Now
For Immediate Orders: Call 1-800-782-8977
(Select option 2 and then option 2 again) OR
Email: elancovet@elancoah.com
Parvovirus FAQs
Always read, understand and follow the label and use directions.
